Insight

Real data of LARCT-US Swedish prospective cohort study on high risk rectal cancer

Photo taken from Bengt Glimelius/X

Aug 18, 2024, 14:58

Real data of LARCT-US Swedish prospective cohort study on high risk rectal cancer

Hyun Kim, Radiation Oncologist at Wash University Radiation Oncology, shared a post on X about a recent paper by Bengt Glimelius et al., commenting:

“LARCT-US Swedish prospective cohort study published! 273 patients with high risk rectal cancer, rapido inclusion, but older and more advanced tumors treated with Short-course radiotherapy (SCRT) and 2 less chemotherapy cycles than rapido. 3-year LRR 6% no more events past 3-years. Real data.”

Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US) published in eClinical Medicine.

Authors: Bengt Glimelius, Tanweera Khan, Karin Adolfsson, Eva Angenete, Åke Berglund, Kristina Bonde, Nils Elander, Tone Fokstuen, Johan Haux, Israa Imam, Cecilia Lagerbäck, Ingrid Ljuslinder, Andrzej Piwowar, Marie Zajicova, Per J. Nilsson.

Additional information
Source: Hyun Kim/X

Bengt Glimelius cancer chemotherapy Hyun Kim Karin Adolfsson LARCT-US Marie Zajicova OncoDaily Oncology Per J. Nilsson rectal cancer Short-course radiotherapy (SCRT) Tanweera Khan

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage